Jiang Zefei

[Expert Profile] Jiang Zefei, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in medical oncology, particularly breast cancer and solid tumor medical treatment in China, working at the Oncology Center, Chinese PLA General Hospital (301 Hospital). He has long been dedicated to comprehensive treatment and individualized precision therapy of advanced refractory solid tumors, and is an important leading figure in medical oncology in China.

[Education & Career] Professor Jiang Zefei graduated from a military medical university, completed systematic oncology training at the Chinese PLA General Hospital, and further studied at famous international cancer centers, systematically mastering cutting-edge international medical oncology treatment techniques. He has long served as Director of the Oncology Center at the Chinese PLA General Hospital, holding important academic positions including Vice President of the Chinese Society of Clinical Oncology (CSCO). He has presided over grants from the National Natural Science Foundation of China and the National Key R&D Program, and is a representative scholar in the field of medical oncology in China.

[Areas of Expertise] Professor Jiang specializes in standardized treatment and whole-course management of breast cancer, as well as comprehensive treatment of advanced refractory solid tumors. He has extensive experience in precise molecular subtyping of breast cancer, endocrine therapy, targeted therapy (HER2-targeted, etc.), immunotherapy, and the rational sequencing of chemotherapy regimens. He excels at developing precise, individualized treatment strategies based on tumor molecular subtypes and patient individual circumstances, helping numerous advanced breast cancer patients achieve long-term survival with tumor and improved quality of life.

[Academic Achievements & Industry Contributions] Professor Jiang has led multiple large-scale Chinese breast cancer clinical studies and real-world studies, systematically evaluating the efficacy and safety of different treatment modalities in Chinese patients, with findings published in authoritative domestic and international journals. He has led the development of Chinese breast cancer diagnosis and treatment guidelines and expert consensus statements, actively advocated for "precision medicine and whole-course management" concepts, promoted the breast cancer MDT (multidisciplinary team) model and standardized diagnosis and treatment system construction, and organized nationwide medical oncology specialist training and multi-center collaborative research, significantly improving the overall diagnosis and treatment level of breast cancer and medical oncology in China.

[Clinical Practice & Outstanding Contributions] Professor Jiang has long held expert medical oncology clinics, cumulatively treating tens of thousands of patients with breast cancer and various tumors, with annual outpatient volume ranking among the highest nationwide. Leading his team, he has developed scientific and humanized treatment plans for countless advanced cancer patients, helping them prolong their lives and improve their quality of life. He has received multiple national and industry honors, and is deeply trusted by patients and respected by peers alike. He is an authoritative expert in the field of medical oncology in China.

[Honors & Reputation] Professor Jiang Zefei serves as Director of the Oncology Department at the Chinese PLA General Hospital and Vice President of the Chinese Society of Clinical Oncology (CSCO), among other academic positions. He has presided over national-level projects including the National Key R&D Program, and is an authoritative expert in the field of medical oncology in China. He has profound expertise in comprehensive treatment of advanced refractory solid tumors and standardized breast cancer diagnosis and treatment. He has led the development of multiple breast cancer diagnosis and treatment guidelines and expert consensus statements, promoted tumor molecular subtyping and precision treatment concepts, and has research findings published in authoritative domestic and international journals, receiving multiple science and technology awards. For decades on the clinical front lines, he has helped numerous advanced cancer patients receive standardized treatment and prolonged survival, and is deeply trusted by patients and respected by peers alike.